Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients.

Blanco-Silvente L, Capellà D, Garre-Olmo J, Vilalta-Franch J, Castells X.

BMC Geriatr. 2018 Jul 24;18(1):168. doi: 10.1186/s12877-018-0857-5.

2.

What seems to matter in public policy and the health of informal caregivers? A cross-sectional study in 12 European countries.

Calvó-Perxas L, Vilalta-Franch J, Litwin H, Turró-Garriga O, Mira P, Garre-Olmo J.

PLoS One. 2018 Mar 8;13(3):e0194232. doi: 10.1371/journal.pone.0194232. eCollection 2018.

3.

Measuring anticholinergic exposure in patients with dementia: A comparative study of nine anticholinergic risk scales.

Turró-Garriga O, Calvó-Perxas L, Vilalta-Franch J, Blanco-Silvente L, Castells X, Capellà D, Garre-Olmo J; Registry of Dementia of Girona Study Group (ReDeGi Study Group).

Int J Geriatr Psychiatry. 2018 May;33(5):710-717. doi: 10.1002/gps.4844. Epub 2018 Jan 2.

PMID:
29292848
4.

Adherence to Clinical Practice Guidelines during Dementia Work-Up in a Real-World Setting: A Study from the Registry of Dementias of Girona.

Turró-Garriga O, Calvó-Perxas L, Vilalta-Franch J, Hernández-Ferrándiz M, Flaqué M, Linares M, Cullell M, Gich J, Casas I, Perkal H, Garre-Olmo J; Registry of Dementia of Girona Study Group (ReDeGi Study Group).

J Alzheimers Dis. 2017;59(3):997-1007. doi: 10.3233/JAD-170284.

PMID:
28697570
5.

Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.

Calvó-Perxas L, Turró-Garriga O, Vilalta-Franch J, Lozano-Gallego M, de Eugenio R, Márquez F, Carmona O, Gich J, Manzano A, Viñas M, Roig AM, Garre-Olmo J; Registry of Dementias of Girona Study Group (ReDeGi Study Group).

Drugs Aging. 2017 Apr;34(4):303-310. doi: 10.1007/s40266-017-0446-x.

PMID:
28258538
6.

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.

Blanco-Silvente L, Castells X, Saez M, Barceló MA, Garre-Olmo J, Vilalta-Franch J, Capellà D.

Int J Neuropsychopharmacol. 2017 Jul 1;20(7):519-528. doi: 10.1093/ijnp/pyx012. Review.

7.

A Path Analysis of Dependence and Quality of Life in Alzheimer's Disease.

Garre-Olmo J, Vilalta-Franch J, Calvó-Perxas L, López-Pousa S; CoDep-AD Study Group.

Am J Alzheimers Dis Other Demen. 2017 Mar;32(2):108-115. doi: 10.1177/1533317516688297. Epub 2017 Jan 22.

PMID:
28110545
8.

[MESGI50 study: description of a cohort on Maturity and Satisfactory Ageing].

Corominas Barnadas JM, López-Pousa S, Vilalta-Franch J, Calvó-Perxas L, Juvinyà Canal D, Garre-Olmo J.

Gac Sanit. 2017 Nov - Dec;31(6):511-517. doi: 10.1016/j.gaceta.2016.07.017. Epub 2016 Oct 24. Spanish.

9.

A path analysis of patient dependence and caregiver burden in Alzheimer's disease.

Garre-Olmo J, Vilalta-Franch J, Calvó-Perxas L, Turró-Garriga O, Conde-Sala L, López-Pousa S.

Int Psychogeriatr. 2016 Jul;28(7):1133-41. doi: 10.1017/S1041610216000223. Epub 2016 Mar 1.

PMID:
26926437
10.

Gender differences in depression and pain: A two year follow-up study of the Survey of Health, Ageing and Retirement in Europe.

Calvó-Perxas L, Vilalta-Franch J, Turró-Garriga O, López-Pousa S, Garre-Olmo J.

J Affect Disord. 2016 Mar 15;193:157-64. doi: 10.1016/j.jad.2015.12.034. Epub 2015 Dec 29.

PMID:
26773909
11.

The Trail Making Test.

Llinàs-Reglà J, Vilalta-Franch J, López-Pousa S, Calvó-Perxas L, Torrents Rodas D, Garre-Olmo J.

Assessment. 2017 Mar;24(2):183-196. doi: 10.1177/1073191115602552. Epub 2016 Jul 28.

PMID:
26318386
12.

Prevalence and sociodemographic correlates of depressive and bipolar disorders in Catalonia (Spain) using DSM-5 criteria.

Calvó-Perxas L, Garre-Olmo J, Vilalta-Franch J.

J Affect Disord. 2015 Sep 15;184:97-103. doi: 10.1016/j.jad.2015.05.048. Epub 2015 Jun 3.

PMID:
26074018
13.

Pharmaceutical consumption and cost in patients with dementia: A longitudinal study by the Registry of Dementias of Girona (ReDeGi) in Catalonia (Spain).

Turró-Garriga O, Calvó-Perxas L, Albaladejo R, Alsina E, Cuy JM, Llinàs-Reglà J, Roig AM, Serena J, Vallmajó N, Viñas M, López-Pousa S, Vilalta-Franch J, Garre-Olmo J; Registry of Dementia of Girona Study Group (ReDeGi Study Group).

Arch Gerontol Geriatr. 2015 May-Jun;60(3):448-52. doi: 10.1016/j.archger.2015.01.020. Epub 2015 Feb 7.

PMID:
25716011
14.

Dependence scale for Alzheimer's disease: relationship with other clinical indicators and psychometric properties.

Garre-Olmo J, Vilalta-Franch J, Calvó-Perxas L, Monserrat-Vila S, López-Pousa S; CoDep-AD Study Group.

J Geriatr Psychiatry Neurol. 2015 Jun;28(2):117-25. doi: 10.1177/0891988714554711. Epub 2014 Oct 20.

PMID:
25330927
15.

Three-year trajectories of caregiver burden in Alzheimer's disease.

Conde-Sala JL, Turró-Garriga O, Calvó-Perxas L, Vilalta-Franch J, Lopez-Pousa S, Garre-Olmo J.

J Alzheimers Dis. 2014;42(2):623-33. doi: 10.3233/JAD-140360.

PMID:
24919767
16.

Abridged scale for the screening anosognosia in patients with dementia.

Turró-Garriga O, Garre-Olmo J, López-Pousa S, Vilalta-Franch J, Reñé-Ramírez R, Conde-Sala JL.

J Geriatr Psychiatry Neurol. 2014 Sep;27(3):220-6. doi: 10.1177/0891988714527515. Epub 2014 Apr 2.

PMID:
24700707
17.

Psychotropic drugs in patients with Alzheimer's Disease: a longitudinal study by the Registry of Dementias of Girona (ReDeGi) in Catalonia, Spain.

Calvó-Perxas L, Turró-Garriga O, Aguirregomozcorta M, Bisbe J, Hernández E, López-Pousa S, Manzano A, Palacios M, Pericot-Nierga I, Perkal H, Ramió L, Vilalta-Franch J, Garre-Olmo J; Registry of Dementias of Girona Study Group (ReDeGi Study Group).

J Am Med Dir Assoc. 2014 Jul;15(7):497-503. doi: 10.1016/j.jamda.2014.02.003. Epub 2014 Mar 14.

PMID:
24637090
18.

Discrepancies regarding the quality of life of patients with Alzheimer's disease: a three-year longitudinal study.

Conde-Sala JL, Turró-Garriga O, Garre-Olmo J, Vilalta-Franch J, Lopez-Pousa S.

J Alzheimers Dis. 2014;39(3):511-25. doi: 10.3233/JAD-131286.

PMID:
24217273
19.

[Cognitive decline in Alzheimer's disease. A follow three or more years of a sample of patients].

Conde-Sala JL, Garre-Olmo J, Vilalta-Franch J, Llinàs-Reglà J, Turró-Garriga O, Lozano-Gallego M, Hernández-Ferràndiz M, Pericot-Nierga I, López-Pousa S.

Rev Neurol. 2013 Jun 16;56(12):593-600. Spanish.

20.

Development of a multidimensional measure of fibromyalgia symptomatology: the comprehensive rating scale for fibromyalgia symptomatology.

López-Pousa S, Garre-Olmo J, de Gracia M, Ribot J, Calvó-Perxas L, Vilalta-Franch J.

J Psychosom Res. 2013 May;74(5):384-92. doi: 10.1016/j.jpsychores.2012.12.018. Epub 2013 Feb 4.

PMID:
23597325

Supplemental Content

Loading ...
Support Center